Type 1 Diabetes Clinical Trial
Official title:
Effect of Gain on Closed-Loop Insulin
The purpose of this study is to test the ability of an advanced external Physiologic Insulin
Delivery (ePID) algorithm (a step by step process used to develop a solution to a problem) to
get acceptable meal responses over a range of gain. Gain is defined as how much insulin is
given in response to a change in a patient's glucose level.
This study also examines the effectiveness of the external Physiologic Insulin Delivery
(ePID) closed-loop insulin delivery computer software. The investigators would like to assess
whether fasting target levels can be achieved as the closed-loop gain increases or decreases,
and to evaluate the system's ability to produce an acceptable breakfast meal response.
There have been significant advances in diabetes management technology, including more
sophisticated insulin pumps and more accurate real-time continuous glucose monitors. The next
technological development is widely thought to be the introduction of an algorithm linking
the pump and sensor to form a closed-loop insulin delivery system. The algorithm used for
this purpose needs to be robust to changes in an individual's insulin sensitivity, and the
sensor's sensitivity to glucose. Insulin sensitivity (how much the patient's glucose level
changes in response to a change in insulin delivery) and algorithm gain (how much insulin is
delivered in response to a change in glucose) determine the systems overall closed-loop gain.
Ideally, the overall gain can be set to achieve the lowest possible peak postprandial glucose
response without postprandial hypoglycemia. However, if the algorithm's gain is set to a
fixed value and the subject's insulin sensitivity changes, the overall-gain will change. Some
degradation in closed-loop performance might be acceptable during periods whenever the
subject's insulin sensitivity is low (i.e., the subject is insulin resistant) and the risk of
hypoglycemia may actually be reduced. However, if the subject becomes more sensitive the
system may become less stable and the risk of postprandial hypoglycemia may increase. In
addition to changes in insulin sensitivity, glucose sensors will sometimes over- or
under-read blood glucose as sensor sensitivity increases or decreases. This will result in a
change in the closed-loop algorithm's effective target. The purpose of this study is to
evaluate the ability of an advanced Physiologic Insulin Delivery algorithm to achieve an
acceptable breakfast response as the gain and effective target glucose level changes.
Specifically:
1. to assess the fasting glucose levels achieved as the overall closed-loop gain and
effective target is increased or decreased, and
2. determine the system's ability to produce an acceptable breakfast meal response under
these conditions
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |